NeOnc Technologies has appointed Ali Alabedin to its board, enhancing its leadership as it progresses clinical trials for brain cancer drugs. Its NEO212 drug is moving toward Phase 2, supported by Abu Dhabi's health authorities for regional development. The company recently reported positive Phase 2a results for NEO100 and plans a key FDA meeting in November to discuss trial design and regulatory pathways. These steps mark important progress in treating difficult brain cancers and expanding NeOnc's global presence.
NeOnc Technologies' boardroom strengthening and brain cancer drug development progress are noted alongside Pluang's health sector market snapshot. As of Oct 14, 2026 21:32 WIB, 93 of 150 health-sector US stocks rose while 55 fell. Halozyme Therapeutics Inc. led gains with a 6.46% increase to USD 116.70 and a typical hold time of 5 days, contrasting with Eli Lilly And Co's price of USD 1,212.50 up 3.94% and a much longer typical hold time of 94 days, while GeneDx Holdings Corp saw a 4.76% rise to USD 68.05 with a near-even Pluang order split and a 20-day hold time.
BlackRock reported a strong third quarter with adjusted earnings of $15.93 per share, beating estimates by a wide margin and marking a 38% increase year-over-year. Revenue grew 19% to $7.75 billion, driven by $205 billion in net client inflows, inclu...
Home BancShares will release its Q3 2026 earnings report on October 14, with analysts expecting earnings per share of $0.64 and revenue around $293-$294 million, marking a 5.5% revenue increase and 4.9% EPS growth from last year. The bank's P/E ratio...
Hyperion Materials & Technologies has acquired The Ultra-Met Company, a tungsten carbide manufacturer based in Urbana, Ohio, to expand its capabilities in serving the US aerospace and defense sectors. Ultra-Met works closely with the US Department of...
Morgan Stanley reported Q3 earnings per share of $3.03, surpassing analyst estimates of $2.93 and $2.83 consensus. Revenue reached $20.34 billion, a 12% increase year-over-year and above the $19.93 billion estimate. Strong equity trading and record w...
Bank of New York Mellon is set to report its Q3 2026 earnings, with analysts expecting earnings per share of $2.27 and revenue of $5.55 billion. This represents an 18.3% increase in earnings and a 9.5% rise in revenue compared to the previous year, d...
